AMC1 MED.B.025 Metabolic and endocrine systems

• ED Decision 2019/002/R found in: Aircrew (1178/2011) Part-FCL Part-MED Part-CC Part-ARA Part-ORA Part-DTO (Dec 2024)

AMC1 MED.B.025 Metabolic and endocrine systems ED Decision 2019/002/R (a)     Metabolic, nutritional or endocrine dysfunction Applicants with metabolic, nutritional or endocrine dysfunction may be assessed as fit if the condition is asymptomatic, clinically compensated and stable with or without replacement therapy, and regularly reviewed by an appropriate specialist. (b)     Obesity Applicants with a Body Mass Index ³ 35 may be assessed as fit only if the excess weight is not likely to interfere with the safe exercise of the applicable licence(s) and the results of a risk assessment, including evaluation of the cardiovascular system and evaluation of the possibility of sleep apnoea, are satisfactory. (c)      Addison’s disease Applicants with Addison’s disease should be assessed as unfit. A fit assessment with an OML may be considered, provided that cortisone is carried and available for use whilst exercising the privileges of the applicable licence(s). (d)     Gout Applicants with acute gout should be assessed as unfit. A fit assessment may be considered once asymptomatic, after cessation of treatment or the condition is stabilised on anti-hyperuricaemic therapy. (e)     Thyroid dysfunction Applicants with hyperthyroidism or hypothyroidism should be assessed as unfit. A fit assessment may be considered when a stable euthyroid state is attained. (f)Abnormal glucose metabolism Glycosuria and abnormal blood glucose levels require investigation. A fit assessment may be considered if normal glucose tolerance is demonstrated (low renal threshold) or impaired glucose tolerance without diabetic pathology is fully controlled by diet and regularly reviewed. (g)     Diabetes mellitus Subject to good control of blood sugar with no hypoglycaemic episodes: (1)     applicants with diabetes mellitus not requiring medication may be assessed as fit; (2)     the use of antidiabetic medications that are not likely to cause hypoglycaemia may be acceptable for a fit assessment with an OML. AMC1 MED.B.025 Metabolic and endocrine systems ED Decision 2019/002/R (a) Metabolic, nutritional or endocrine dysfunction Applicants with metabolic, nutritional or endocrine dysfunction may be assessed as fit if the condition is asymptomatic, clinically compensated and stable with or without replacement therapy, and regularly reviewed by an appropriate specialist. (b) Obesity Applicants with a Body Mass Index ³ 35 may be assessed as fit only if the excess weight is not likely to interfere with the safe exercise of the applicable licence(s) and the results of a risk assessment, including evaluation of the cardiovascular system and evaluation of the possibility of sleep apnoea, are satisfactory. (c) Addison’s disease Applicants with Addison’s disease should be assessed as unfit. A fit assessment with an OML may be considered, provided that cortisone is carried and available for use whilst exercising the privileges of the applicable licence(s). (d) Gout Applicants with acute gout should be assessed as unfit. A fit assessment may be considered once asymptomatic, after cessation of treatment or the condition is stabilised on anti-hyperuricaemic therapy. (e) Thyroid dysfunction Applicants with hyperthyroidism or hypothyroidism should be assessed as unfit. A fit assessment may be considered when a stable euthyroid state is attained. (f)Abnormal glucose metabolism Glycosuria and abnormal blood glucose levels require investigation. A fit assessment may be considered if normal glucose tolerance is demonstrated (low renal threshold) or impaired glucose tolerance without diabetic pathology is fully controlled by diet and regularly reviewed. (g) Diabetes mellitus Subject to good control of blood sugar with no hypoglycaemic episodes: (1) applicants with diabetes mellitus not requiring medication may be assessed as fit; (2) the use of antidiabetic medications that are not likely to cause hypoglycaemia may be acceptable for a fit assessment with an OML. ##### AMC1 MED.B.025 Metabolic and endocrine systems *ED Decision 2019/002/R* (a) Metabolic, nutritional or endocrine dysfunction Applicants with metabolic, nutritional or endocrine dysfunction may be assessed as fit if the condition is asymptomatic, clinically compensated and stable with or without replacement therapy, and regularly reviewed by an appropriate specialist. (b) Obesity Applicants with a Body Mass Index ³ 35 may be assessed as fit only if the excess weight is not likely to interfere with the safe exercise of the applicable licence(s) and the results of a risk assessment, including evaluation of the cardiovascular system and evaluation of the possibility of sleep apnoea, are satisfactory. (c) Addison’s disease Applicants with Addison’s disease should be assessed as unfit. A fit assessment with an OML may be considered, provided that cortisone is carried and available for use whilst exercising the privileges of the applicable licence(s). (d) Gout Applicants with acute gout should be assessed as unfit. A fit assessment may be considered once asymptomatic, after cessation of treatment or the condition is stabilised on anti-hyperuricaemic therapy. (e) Thyroid dysfunction Applicants with hyperthyroidism or hypothyroidism should be assessed as unfit. A fit assessment may be considered when a stable euthyroid state is attained. (f)Abnormal glucose metabolism Glycosuria and abnormal blood glucose levels require investigation. A fit assessment may be considered if normal glucose tolerance is demonstrated (low renal threshold) or impaired glucose tolerance without diabetic pathology is fully controlled by diet and regularly reviewed. (g) Diabetes mellitus Subject to good control of blood sugar with no hypoglycaemic episodes: (1) applicants with diabetes mellitus not requiring medication may be assessed as fit; (2) the use of antidiabetic medications that are not likely to cause hypoglycaemia may be acceptable for a fit assessment with an OML.